Preamble Limits Claim Where Body Of Claim Fails To Recite Complete Invention
Client Alert | 1 min read | 03.22.06
In Bicon, Inc. v. Straumann Co. (No. 05-1168; March 20, 2006), the Federal Circuit affirms the district court's grant of summary judgment of noninfringement. Bicon and Diro, Inc. sued Straumann for infringement of a patent for a dental implant prosthesis, i.e., an emergence cuff member for use in preserving interdental papilla. Central to the claim construction and infringement analyses of the Federal Circuit is a determination of whether the preamble of the claim at issue limits the claim.
The Federal Circuit finds that the preamble of the claim recites essential elements of the invention pertaining to the structure of an abutment that is used with the claimed emergence cuff, because the preamble contains structural features of the abutment, and the body of the claim refers back to the features of the abutment described in the preamble. Moreover, the Federal Circuit determines that if the claim is not limited by the preamble, some of the limitations of the claim would be rendered meaningless. Thus, the Federal Circuit concludes that the preamble limits the claim.
Insights
Client Alert | 8 min read | 06.30.25
AI Companies Prevail in Path-Breaking Decisions on Fair Use
Last week, artificial intelligence companies won two significant copyright infringement lawsuits brought by copyright holders, marking an important milestone in the development of the law around AI. These decisions – Bartz v. Anthropic and Kadrey v. Meta (decided on June 23 and 25, 2025, respectively), along with a February 2025 decision in Thomson Reuters v. ROSS Intelligence – suggest that AI companies have plausible defenses to the intellectual property claims that have dogged them since generative AI technologies became widely available several years ago. Whether AI companies can, in all cases, successfully assert that their use of copyrighted content is “fair” will depend on their circumstances and further development of the law by the courts and Congress.
Client Alert | 3 min read | 06.30.25
Client Alert | 3 min read | 06.26.25
FDA Targets Gene Editing Clinical Trials in China and other “Hostile Countries”
Client Alert | 3 min read | 06.26.25
